Timothy Pylko
Psychiatry · San Marino, CANPI 1841328705
Payments from drug & device makers
Across 391 payments — averaging $279.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$48K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$35K
- Teva Pharmaceuticals USA, Inc.$20K
- Sunovion Pharmaceuticals Inc.$1K
- Alkermes, Inc.$790
- Johnson & Johnson$750
- plus $2K from 17 others
What the payments were for
- Consulting fees$5,3905%
- Speaking & faculty fees$88,96981%
- Travel & lodging$5,0185%
- Food & beverage$9,7419%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 121 | $48,259 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $35,178 |
| Teva Pharmaceuticals USA, Inc. | 52 | $20,367 |
| Sunovion Pharmaceuticals Inc. | 21 | $1,429 |
| Alkermes, Inc. | 40 | $790 |
| Johnson & Johnson | 12 | $750 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $526 |
| Otsuka America Pharmaceutical, Inc. | 15 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $302 |
| E.r. Squibb & Sons, L.L.C. | 8 | $297 |
| Lundbeck LLC | 16 | $220 |
| Neurocrine Biosciences, Inc. | 6 | $146 |
| Vanda Pharmaceuticals Inc. | 5 | $143 |
| Axsome Therapeutics, Inc. | 5 | $128 |
| Indivior Inc. | 2 | $124 |
| Bausch Health US, LLC | 3 | $59 |
| Merck | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Tris Pharma Inc | 2 | $32 |
| Almatica Pharma LLC | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Corium, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$46,860
- CAPLYTA$34,472
- UZEDY$15,061
- AUSTEDO$3,081
- LATUDA$1,069
- ARISTADA$452
- INVEGA SUSTENNA$297
- INVEGA TRINZA$147
- SPRAVATO$125
- INVEGA$125
- COBENFY$122
- Austedo XR$114
- ARISTADA INITIO$113
- PERSERIS$106
How this compares
$109,229 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 26 | $40,928 |
| VraylarCariprazine Hcl | 22 | $38,401 |
| Lurasidone Hcl | 57 | $12,917 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,727 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $11,278 |
| Aripiprazole | 81 | $7,130 |
| Clozapine OdtClozapine | 15 | $6,602 |
| Clozapine | 65 | $3,992 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $3,230 |
| Bupropion XlBupropion Hcl | 128 | $2,452 |
| Lamotrigine | 164 | $2,280 |
| Duloxetine Hcl | 103 | $1,980 |
| Oxcarbazepine | 18 | $1,847 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 44 | $1,507 |
| Quetiapine Fumarate | 102 | $1,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $35,178 | $40,92826 claims |
| AbbVieVraylar | $48,259 | $38,40122 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $302 | $23,00548 claims |
| Almatica Pharma LLCSertraline Hcl | $25 | $21939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Marino
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.